{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:08:35Z","timestamp":1792505315559,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,1,5]],"date-time":"2010-01-05T00:00:00Z","timestamp":1262649600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1007\/s00296-009-1357-x","type":"journal-article","created":{"date-parts":[[2010,1,4]],"date-time":"2010-01-04T15:59:15Z","timestamp":1262620755000},"page":"787-790","source":"Crossref","is-referenced-by-count":11,"title":["Multiple organ tuberculosis of lung, pleura, and peritoneum in ankylosing spondylitis during adalimumab therapy"],"prefix":"10.1007","volume":"32","author":[{"given":"Wan-Hee","family":"Yoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,1,5]]},"reference":[{"issue":"7","key":"1357_CR1","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D Heijde van der","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC Jr, ATLAS Study Group (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54(7):2136\u20132146","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1357_CR2","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/ard.2005.041137","volume":"65","author":"J Zochling","year":"2006","unstructured":"Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, Dougados M, G\u00e9her P, Inman RD, Khan MA, Kvien TK, Leirisalo-Repo M, Olivieri I, Pavelka K, Sieper J, Stucki G, Sturrock RD, van der Linden S, Wendling D, B\u00f6hm H, van Royen BJ, Braun J (2006) \u2018ASsessment in AS\u2019 international working group; European League Against Rheumatism (ASAS\/EULAR) recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 65(4):442\u2013452","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1357_CR3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/187221307779815039","volume":"1","author":"E Toussirot","year":"2007","unstructured":"Toussirot E, Streit G, Wendling D (2007) Infectious complications with anti-TNFalpha therapy in rheumatic diseases: a review. Recent Pat Inflamm Allergy Drug Discov 1(1):39\u201347","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"issue":"6","key":"1357_CR4","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.berh.2006.08.010","volume":"20","author":"A Strangfeld","year":"2006","unstructured":"Strangfeld A, Listing J (2006) Infection and musculoskeletal conditions: bacterial and opportunistic infections during anti-TNF therapy. Best Pract Res Clin Rheumatol 20(6):1181\u20131195","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"11","key":"1357_CR5","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s00296-008-0837-8","volume":"29","author":"VF Azevedo","year":"2009","unstructured":"Azevedo VF, Parchen C, Coelho SA, Lacerda DC, Hirth CG (2009) Tuberculous myositis in a patient with ankylosing spondylitis treated with adalimumab. Rheumatol Int 29(11):1381\u20131384","journal-title":"Rheumatol Int"},{"issue":"15","key":"1357_CR6","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345(15):1098\u20131104","journal-title":"N Engl J Med"},{"issue":"4","key":"1357_CR7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/art.1780380407","volume":"38","author":"J Braun","year":"1995","unstructured":"Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, Eggens U, Distler A, Sieper J (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38(4):499\u2013505","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1357_CR8","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/art.21563","volume":"54","author":"H Haibel","year":"2006","unstructured":"Haibel H, Rudwaleit M, Brandt HC, Grozdanovic Z, Listing J, Kupper H, Braun J, Sieper J (2006) Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum 54(2):678\u2013681","journal-title":"Arthritis Rheum"},{"issue":"12","key":"1357_CR9","first-page":"2563","volume":"30","author":"DE Furst","year":"2003","unstructured":"Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK (2003) Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 30(12):2563\u20132571","journal-title":"J Rheumatol"},{"issue":"1","key":"1357_CR10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","volume":"48","author":"ME Weinblatt","year":"2003","unstructured":"Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48(1):35\u201345","journal-title":"Arthritis Rheum"},{"issue":"21","key":"1357_CR11","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra032906","volume":"350","author":"NJ Olsen","year":"2004","unstructured":"Olsen NJ, Stein CM (2004) New drugs for rheumatoid arthritis. N Engl J Med 350(21):2167\u20132179","journal-title":"N Engl J Med"},{"issue":"9","key":"1357_CR12","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1592\/phco.2005.25.9.1181","volume":"25","author":"DJ Rychly","year":"2005","unstructured":"Rychly DJ, Dipiro JT (2005) Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 25(9):1181\u20131192","journal-title":"Pharmacotherapy"},{"issue":"4","key":"1357_CR13","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1517\/14740338.4.4.637","volume":"4","author":"N Scheinfeld","year":"2005","unstructured":"Scheinfeld N (2005) Adalimumab: a review of side effects. Expert Opin Drug Saf 4(4):637\u2013641","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"1357_CR14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1086\/421494","volume":"39","author":"AK Mohan","year":"2004","unstructured":"Mohan AK, Cot\u00e9 TR, Block JA, Manadan AM, Siegel JN, Braun MM (2004) Tuberculosis following the use of etarnecept, a tumor necrosis factor inhibitor. Clin Infect Dis 39(3):295\u2013299","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1357_CR15","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.rdc.2004.01.003","volume":"30","author":"J Bieber","year":"2004","unstructured":"Bieber J, Kavanaugh A (2004) Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biological treatments. Rheum Dis Clin North Am 30(2):257\u2013270","journal-title":"Rheum Dis Clin North Am"},{"issue":"8","key":"1357_CR16","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/00365540701877320","volume":"40","author":"J Antol\u00edn","year":"2008","unstructured":"Antol\u00edn J, Azahara M, Hern\u00e1ndez C, Blanco M, Mao L, Cig\u00fcenza R (2008) Tuberculous peritonitis after treatment with adalimumab. Scand J Infect Dis 40(8):677\u2013678","journal-title":"Scand J Infect Dis"},{"issue":"3","key":"1357_CR17","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s10067-005-0164-3","volume":"26","author":"A Guti\u00e9rrez-Mac\u00edas","year":"2007","unstructured":"Guti\u00e9rrez-Mac\u00edas A, Lizarralde-Palacios E, Mart\u00ednez-Odriozola P, Miguel-de la Villa F (2007) Tuberculous peritonitis in a patient with rheumatoid arthritis treated with adalimumab. Clin Rheumatol 26(3):452\u2013453","journal-title":"Clin Rheumatol"},{"issue":"3","key":"1357_CR18","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/rheumatology\/ken469","volume":"48","author":"AL Endean","year":"2009","unstructured":"Endean AL, Barry SM, Young-Min SA (2009) Possible miliary tuberculosis during adalimumab therapy with negative gamma-IFN release assays. Rheumatology (Oxford) 48(3):319\u2013320","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"1357_CR19","first-page":"1436","volume":"30","author":"L Carmona","year":"2003","unstructured":"Carmona L, Hern\u00e1ndez-Garc\u00eda C, Vadillo C, Pato E, Balsa A, Gonz\u00e1lez-Alvaro I, Study Group EMECAR (2003) Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 30(7):1436\u20131439","journal-title":"J Rheumatol"},{"issue":"2","key":"1357_CR20","first-page":"217","volume":"69","author":"P Stas","year":"2006","unstructured":"Stas P, D\u2019Hoore A, Van Assche G, Geboes K, Steenkiste E, Penninckx F, Rutgeerts P, Vermeire S (2006) Miliary tuberculosis following infliximab therapy for Crohn disease: a case report and review of the literature. Acta Gastroenterol Belg 69(2):217\u2013220","journal-title":"Acta Gastroenterol Belg"},{"issue":"3","key":"1357_CR21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.7326\/0003-4819-149-3-200808050-00241","volume":"149","author":"M Pai","year":"2008","unstructured":"Pai M, Zwerling A, Menzies D (2008) Systematic review: T-cell based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 149(3):177\u2013184","journal-title":"Ann Intern Med"},{"issue":"9519","key":"1357_CR22","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/S0140-6736(06)68579-6","volume":"367","author":"G Ferrara","year":"2006","unstructured":"Ferrara G, Losi M, D\u2019Amico R, Roversi P, Piro R, Meacci M, Meccugni B, Dori IM, Andreani A, Bergamini BM, Mussini C, Rumpianesi F, Fabbri LM, Richeldi L (2006) Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 367(9519):1328\u20131334","journal-title":"Lancet"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-009-1357-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-009-1357-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-009-1357-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T11:18:39Z","timestamp":1559042319000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-009-1357-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,5]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["1357"],"URL":"https:\/\/doi.org\/10.1007\/s00296-009-1357-x","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,5]]}}}